Part D Prescription Drug

FDA Approves Semglee : Substitute Insulin for Treatment of Diabetes

The U.S. Food and Drug Administration took action this week that should make it easier to get a lower cost near-copy of a brand-name insulin, Lantus, at the pharmacy.      Semglee has been approved as both biosimilar to, and interchangeable as a substitute for Lantus, a widely used long-acting insulin. Biosimilar drugs are not […]